1. Home
  2. EML vs CRDF Comparison

EML vs CRDF Comparison

Compare EML & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastern Company (The)

EML

Eastern Company (The)

HOLD

Current Price

$21.72

Market Cap

119.2M

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.58

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EML
CRDF
Founded
1858
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.2M
130.7M
IPO Year
1995
2012

Fundamental Metrics

Financial Performance
Metric
EML
CRDF
Price
$21.72
$1.58
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
13.0K
602.0K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
2.03%
N/A
EPS Growth
185.40
27.37
EPS
1.17
N/A
Revenue
$248,970,345.00
$365,993.00
Revenue This Year
$19.05
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$18.55
N/A
Revenue Growth
N/A
49.61
52 Week Low
$17.61
$1.48
52 Week High
$26.76
$4.56

Technical Indicators

Market Signals
Indicator
EML
CRDF
Relative Strength Index (RSI) 69.74 40.13
Support Level $21.76 $1.51
Resistance Level $24.15 $1.68
Average True Range (ATR) 0.60 0.09
MACD 0.11 0.00
Stochastic Oscillator 98.85 12.12

Price Performance

Historical Comparison
EML
CRDF

About EML Eastern Company (The)

The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: